Evaluate (Post Approval) the Adherence to the Prescribing Information for ARIXTRA (R) (Fondaparinux) in ACS Patients- Commitment of the Fondaparinux EU-RMP.
Phase of Trial: Phase IV
Latest Information Update: 30 Apr 2015
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 02 Sep 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 02 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2011 New trial record